Nothing to cheer about Sun Pharma's FY20 guidance, says Research Delta Advisor

CNBC-TV18 2019-05-29

Views 2

Nimish Mehta, founder and director of Research Delta Advisor shared his take on Sun Pharmaceutical Industries' earnings.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
We continue to maintain the overall 14 to 16 percent guidance for FY20, says Prateek Aggarwal of HCL Tech
play
10:55

We continue to maintain the overall 14 to 16 percent guidance for FY20, says Prateek Aggarwal of HCL Tech
Infosys Hikes FY20 Revenue Guidance
play
02:36

Infosys Hikes FY20 Revenue Guidance
Arvind Confident Of Meeting FY20 Guidance
play
06:44

Arvind Confident Of Meeting FY20 Guidance
Ashok Leyland on FY20-FY21 guidance
play
11:12

Ashok Leyland on FY20-FY21 guidance
Nasscom on why they have held back FY20 guidance
play
11:51

Nasscom on why they have held back FY20 guidance
Blue Star's Growth Guidance For FY20
play
13:41

Blue Star's Growth Guidance For FY20
Muthoot Finance Maintains FY20 Gold Loan AUM Guidance
play
07:48

Muthoot Finance Maintains FY20 Gold Loan AUM Guidance
APL Apollo On FY20 Guidance, Debt Reduction Plan & More
play
06:02

APL Apollo On FY20 Guidance, Debt Reduction Plan & More
HCL Tech Management Is Confident Of Delivering On Its FY20 Guidance
play
10:29

HCL Tech Management Is Confident Of Delivering On Its FY20 Guidance
Will surpass earlier guidance of 40% growth for FY20, says Dixon Technologies
play
06:45

Will surpass earlier guidance of 40% growth for FY20, says Dixon Technologies
Parag Milk's Robust FY20 Revenue Guidance
play
04:51

Parag Milk's Robust FY20 Revenue Guidance
JSW Steel Optimistic Of Meeting FY20 Sales Guidance
play
15:03

JSW Steel Optimistic Of Meeting FY20 Sales Guidance